Track Sage Therapeutics's accounts payable ($690K) with charts, peers, and YoY trends.
Get informed when a big investor buys or sells
+ FollowLatest change versus the prior comparable period (same company).
As of the most recent data (June 2025), SAGE shows a accounts payable of $690K. That compares with $8.7M in the prior-year period — down 92.0% year over year. Scroll down for historical charts and peer comparison views.
Compared with the year-ago period, SAGE's accounts payable is now $690K (was $8.7M) — a 92.0% year-over-year decrease. Pairing that YoY change with peer averages gives a clearer picture of whether Sage Therapeutics is outperforming or lagging.
Tracking SAGE's accounts payable over time shows whether Sage Therapeutics is scaling, shrinking, or reshaping that part of the business. The current reading is $690K That compares with $8.7M in the prior-year period — down 92.0% year over year. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.
Besides this accounts payable page, Stockcircle has Sage Therapeutics's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect accounts payable (currently $690K) with ownership activity and broader fundamentals.
Sage Therapeutics's accounts payable is $690K; compare it with other Healthcare names on the peer chart. Typical ranges vary by sub-industry, so always sanity-check against the closest competitors, not just the whole sector bucket.